- Home
- ESPR vs OABI Comparison
ESPR vs OABI Comparison
Compare ESPR & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- OABI
- Stock Information
- Founded
- ESPR 2008
- OABI 2012
- Country
- ESPR United States
- OABI United States
- Employees
- ESPR N/A
- OABI N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- ESPR Health Care
- OABI Health Care
- Exchange
- ESPR Nasdaq
- OABI Nasdaq
- Market Cap
- ESPR 208.1M
- OABI 198.2M
- IPO Year
- ESPR 2013
- OABI N/A
- Fundamental
- Price
- ESPR $1.07
- OABI $1.60
- Analyst Decision
- ESPR Buy
- OABI Strong Buy
- Analyst Count
- ESPR 7
- OABI 3
- Target Price
- ESPR $5.93
- OABI $7.00
- AVG Volume (30 Days)
- ESPR 4.1M
- OABI 1.1M
- Earning Date
- ESPR 08-11-2025
- OABI 08-07-2025
- Dividend Yield
- ESPR N/A
- OABI N/A
- EPS Growth
- ESPR N/A
- OABI N/A
- EPS
- ESPR N/A
- OABI N/A
- Revenue
- ESPR $259,574,000.00
- OABI $26,744,000.00
- Revenue This Year
- ESPR $4.07
- OABI N/A
- Revenue Next Year
- ESPR N/A
- OABI $45.65
- P/E Ratio
- ESPR N/A
- OABI N/A
- Revenue Growth
- ESPR 12.99
- OABI 27.07
- 52 Week Low
- ESPR $0.69
- OABI $1.22
- 52 Week High
- ESPR $3.94
- OABI $4.96
- Technical
- Relative Strength Index (RSI)
- ESPR 51.40
- OABI 54.70
- Support Level
- ESPR $1.13
- OABI $1.35
- Resistance Level
- ESPR $1.22
- OABI $1.81
- Average True Range (ATR)
- ESPR 0.08
- OABI 0.10
- MACD
- ESPR 0.00
- OABI 0.04
- Stochastic Oscillator
- ESPR 52.38
- OABI 71.96
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.